Amanda M. Dinofia

Hematology | Oncology
3500 Civic Center Blvd
Philadelphia, PA 19104

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications

Differential cytokine architecture in patients treated with CART19 versus CART22.

Differential cytokine architecture in patients treated with CART19 versus CART22.

Journal: Journal for immunotherapy of cancer
Published: May 21, 2026

CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multisite, retrospective cohort review.

CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multisite, retrospective cohort review.

Journal: Blood advances
Published: October 01, 2025

CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia.

CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia.

Journal: Blood advances
Published: September 29, 2025

CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia.

CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia.

Journal: Blood advances
Published: September 29, 2025

Preinfusion risk factors for the development of severe neurotoxicity following CART therapy in pediatric patients.

Preinfusion risk factors for the development of severe neurotoxicity following CART therapy in pediatric patients.

Journal: HemaSphere
Published: June 26, 2025

Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemia.

Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemia.

Journal: Haematologica
Published: May 29, 2025

CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy.

CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy.

Journal: Journal for immunotherapy of cancer
Published: April 01, 2025

Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapy.

Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapy.

Journal: Blood advances
Published: August 13, 2024

Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies.

Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies.

Journal: Nature medicine
Published: April 23, 2024

Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia.

Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia.

Journal: Blood advances
Published: February 07, 2024

Quadriparesis and paraparesis following chimeric antigen receptor T-cell therapy in children and adolescents.

Quadriparesis and paraparesis following chimeric antigen receptor T-cell therapy in children and adolescents.

Journal: Blood
Published: January 16, 2024

Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients.

Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients.

Journal: Blood advances
Published: May 11, 2023
Showing 1-12 of 34

Last Updated: 09/26/2026